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Abstract
Introduction: Although early institution of adequate antimicrobial therapy is lifesaving in sepsis patients, optimal
antimicrobial strategy has not been established. Moreover, the benefit of combination therapy over monotherapy
remains to be determined. Our aims are to describe patterns of empiric antimicrobial therapy in severe sepsis,
assessing the impact of combination therapy, including antimicrobials with different mechanisms of action, on
mortality.
Methods: This is a Spanish national multicenter study, analyzing all patients admitted to ICUs who received
antibiotics within the first 6 hours of diagnosis of severe sepsis or septic shock. Antibiotic-prescription patterns in
community-acquired infections and nosocomial infections were analyzed separately and compared. We compared
the impact on mortality of empiric antibiotic treatment, including antibiotics with different mechanisms of action,
termed different-class combination therapy (DCCT), with that of monotherapy and any other combination therapy
possibilities (non-DCCT).
Results: We included 1,372 patients, 1,022 (74.5%) of whom had community-acquired sepsis and 350 (25.5%) of
whom had nosocomial sepsis. The most frequently prescribed antibiotic agents were b-lactams (902, 65.7%) and
carbapenems (345, 25.1%). DCCT was administered to 388 patients (28.3%), whereas non-DCCT was administered to
984 (71.7%). The mortality rate was significantly lower in patients administered DCCTs than in those who were
administered non-DCCTs (34% versus 40%; P = 0.042). The variables independently associated with mortality were
age, male sex, APACHE II score, and community origin of the infection. DCCT was a protective factor against in-
hospital mortality (odds ratio (OR), 0.699; 95% confidence interval (CI), 0.522 to 0.936; P = 0.016), as was urologic
focus of infection (OR, 0.241; 95% CI, 0.102 to 0.569; P = 0.001).
Conclusions: b-Lactams, including carbapenems, are the most frequently prescribed antibiotics in empiric therapy
in patients with severe sepsis and septic shock. Administering a combination of antimicrobials with different
mechanisms of action is associated with decreased mortality.
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Introduction
Sepsis is a prevalent disorder and one of the main causes
of death among hospitalized patients. Treating sepsis is
associated with high costs; however, despite advances in
medical practice, the mortality rate of sepsis has not
declined in recent decades [1]. In Spain, the incidence of
severe sepsis is 104 cases per 100,000 adult residents per
year, and related in-hospital mortality is 20.7%; the inci-
dence of septic shock is 31 cases per 100,000 adult resi-
dents per year, and related in-hospital mortality is 45.7%
[2]. Sepsis present at intensive care unit (ICU) admission
and ICU-acquired sepsis clearly differ in the types of
patients affected, the sources of infection, the microor-
ganisms responsible, and the prognosis [3].
Diverse studies have confirmed that the prompt institu-
tion of antimicrobial therapy active against the causative
pathogen is lifesaving in patients with severe sepsis [4,5].
The Surviving Sepsis Campaign strongly recommends
initiating antibiotic therapy within the first hour of recog-
nition of severe sepsis, after suitable samples have been
obtained for cultures [6].
Nevertheless, although antibiotic therapy is the corner-
stone in the treatment of sepsis, the optimal antimicro-
bial strategy has not been defined. Few data are available
about antibiotic prescription patterns used most in severe
sepsis.
Furthermore, the advantages and disadvantages of
combination therapy compared with monotherapy are
controversial, and studies comparing the two approaches
have mainly been limited to bacteremia, pneumonia, or
serious Pseudomonas aeruginosa infections [7-9]. Impor-
tantly, a recent retrospective study concluded that certain
combinations of antimicrobials, including antimicrobials
with different targets, improve survival in patients with
septic shock [10].
We present a secondary analysis of the Edusepsis study,
which enrolled all patients with severe sepsis and septic
shock admitted to the participating ICUs during 2 months
in 2005 and 4 months in 2006. Our aims are (a) to
describe the patterns of empiric antimicrobial therapy,
analyzing the differences between community-acquired
and nosocomial infections; and (b) to compare the impact
on mortality of combination therapy, including at least
two antimicrobials with different mechanisms of action,
with that of monotherapy and other combinations of
antimicrobials.
Materials and methods
Design of the study
We conducted a secondary analysis of the Edusepsis
study, a Spanish national multicenter before-and-after
study involving 77 ICUs [11]. In this study, carried out
between November 2005 and 2007, data were collected
before and after a 2-month educational intervention
based on the Surviving Sepsis Campaign guidelines; this
approach to improving treatment of severe sepsis is cost-
effective [12]. Each participating centers’ research and
ethical-review boards approved the study, and patients
remained anonymous. The need for informed consent
was waived in view of the observational and anonymous
nature of the study.
The study included all patients in these ICUs with
severe sepsis or septic shock. The study design is
described in detail elsewhere [11]. In brief, severe sepsis
was defined as sepsis associated with organ dysfunction
unexplained by other causes. Septic shock was defined as
sepsis associated with systolic blood pressure <90 mm
Hg, mean arterial pressure <65 mm Hg, or a reduction in
systolic blood pressure >40 mm Hg from baseline despite
adequate volume resuscitation. Patients in whom the
onset of severe sepsis could not be determined were
excluded from the analysis. The approach to data collec-
tion and the quality-control measures to assure data
reliability also are described elsewhere [11,12].
Variables
The following variables were recorded: demographic
characteristics (age and gender), types of patients (medi-
cal, trauma, emergency surgery, elective surgery), sources
of infection, location at sepsis acquisition (community-
acquired or nosocomial infection), and baseline lactate
level and organ dysfunction at sepsis diagnosis. Severity
of illness was evaluated by the Acute Physiology and
Chronic Health Evaluation (APACHE) II score, consider-
ing the worst reading in the first 24 hours in the ICU
[13]. All patients were followed up until death or hospital
discharge. The primary outcome variable was in-hospital
mortality.
Antimicrobial therapy
The antimicrobial therapy prescribed at the diagnosis of
severe sepsis and the time from severe sepsis presenta-
tion to antibiotic administration were recorded. To facili-
tate subsequent analysis, antimicrobial agents were
grouped into eight antibiotic families: b-lactams (except
carbapenems), carbapenems, quinolones, macrolides,
aminoglycosides, anti-gram-positive antibiotics (vanco-
mycin, teicoplanin, and linezolid), antifungal agents, and
other antimicrobial agents (including antiviral and tuber-
culostatic agents). Data for community-acquired and
nosocomial infections also were analyzed separately. We
also compared the clinical characteristics of patients that
received different-class combination therapy (DCCT)
with those of patients that received any other antimicro-
bial therapy (non-DCCT).
DCCT was defined as the concomitant use of two or
more antibiotics of different mechanistic classes, as recently
defined by Kumar et al. [10], specifically b-lactams or
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carbapenems with aminoglycosides, fluoroquinolones, or
macrolides/clindamycin. Monotherapy or any other combi-
nation therapy was considered non-DCCT for this analysis.
To assess the impact of DCCT on mortality, we analyzed
only patients who received the first dose of antimicrobial
within the first 6 hours after severe sepsis presentation.
Statistical analysis
Discrete variables were expressed as frequencies (percen-
tage), and continuous variables, as means and standard
deviations (SDs), unless stated otherwise; all statistical
tests were two-sided. Differences in categoric variables
were calculated by using c2 tests or Fisher Exact test, and
differences in continuous variables were calculated by
using the Mann-Whitney U or Kruskal-Wallis test, as
appropriate.
Backward logistic regression was used to assess the fac-
tors independently associated with in-hospital mortality.
To avoid spurious associations, variables entered in the
regression models were those with a relation in univariate
analysis (P ≤ 0.05) or a plausible relation with the depen-
dent variable. SPSS for Windows 20.0 (SPSS, Chicago, IL,
USA) was used for all statistical analyses.
Results and discussion
Descriptive analysis
The Edusepsis study included 2,796 patients with severe
sepsis or septic shock; we analyzed the 1,372 patients
that received antibiotic therapy in the first 6 hours from
the diagnosis of sepsis, of whom 1,022 (74.5%) had com-
munity-acquired sepsis and 350 (25.5%) had nosocomial
sepsis. Table 1 shows the study group’s main demo-
graphics, APACHE II scores, levels of lactate, and diag-
noses on admission.
The most frequent sources of sepsis were pneumonia
(n = 502; 36.6%), followed by abdominal infection (n =
390; 28.48%), urinary tract infection (n = 182; 13.3%),
central nervous system infection (n = 50; 3.6%), skin or
soft-tissue infection (n = 54; 3.9%), and catheter-related
infection (n = 24; 1.7%).
Table 1 Demographic and clinical characteristics of the patients
Global
n = 1,372
Community-acquired
n = 1,022 (74.5%)
Nosocomial
n = 350 (25.5%)
P
General data
Sex (male) 837 (61%) 623 (61%) 214 (61%) 0.999
Age (years) 62.24 ± 16.22 62.00 ± 16.65 62.93 ± 14.87 0.354
APACHE II 21.44 ± 7.54 21.09 ± 7.49 22.45 ± 7.61 0.004
Lactate (mM) 35.56 ± 26.94 36.76 ± 27.68 32.06 ± 24.37 0.020
Diagnosis on admission
Medical 893 (65.4%) 734 (72%) 159 (45.8%)
Trauma 25 (1.8%) 8 (0.8%) 17 (4.9%) <0.001
Emergency surgery 382 (28%) 256 (25.1%) 126 (36.3%)
Elective surgery 66 (4.86%) 21 (2.1%) 45 (13%)
Type of infection
Pneumonia 502 (36.6%) 362 (35.4%) 140 (40%)
Abdominal 390 (28.4%) 270 (26.4%) 120 (34.3%)
Urologic 182 (13.3%) 163 (15.9%) 19 (5.4%)
Meningitis 50 (3.6%) 47 (4.6%) 3 (0.9%) <0.001
SSTI 54 (3.9%) 46 (4.5%) 8 (2.3%)
Catheter 24 (1.7%) 6 (0.6%) 18 (5.1%)
Others 138 (3.1%) 108 (10.6%) 30 (8.6%)
More than one focus 32 (2.3%) 20 (2.0%) 12 (3.4%)
Organ failure
Hemodynamic 1,129 (82.3%) 845 (82.7%) 284 (81.1%) 0.517
Respiratory 880 (64.1%) 641 (62.7%) 239 (68.3%) 0.062
Renal ,1006 (73.3%) 754 (73.8%) 252 (72.0%) 0.529
Hepatic 238 (17.3%) 176 (17.2%) 62 (17.7%) 0.870
Hematologic 344 (25.1%) 266 (26.0%) 78 (22.3%) 0.175
Coagulation 502 (36.6%) 394 (38.6%) 108 (30.9%) 0.010
Mortality 526 (38.3%) 356 (34.8%) 170 (48.6%) <0.001
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Antimicrobial treatments prescribed
The most frequently prescribed antibiotic agents were b-
lactams (n = 902; 65.7%), carbapenems (n = 345; 25.1%),
and quinolones (n = 282; 20.6%). Table 2 presents the
data for the entire group of patients who received empiric
antibiotic therapy within 6 hours of admission, and for
the groups of patients with community-acquired (n =
1,022; 74.5%) and nosocomial infections (n = 350; 25.5%).
The distribution of the antibiotics prescribed for commu-
nity-acquired infections was similar to that for the overall
group, with predominance of b-lactams (n = 708; 69.3%),
quinolones (n = 241; 23.6%), and carbapenems (n = 218;
21.3%), , whereas in the group with nosocomial infections,
although b-lactams were also the most-used treatment
(n = 194; 55.4%), carbapenems were second (n = 127;
36.3%), followed by aminoglycosides (n = 69; 19.7%) and
anti-gram-positive agents (n = 65; 18.6%). Macrolides and
quinolones were more frequently used in community-
acquired sepsis than in nosocomial sepsis (see Table 2).
DCCT and non-DCCT groups
DCCTs were administered to 388 patients (28.3%), and
non-DCCTs, to 984 (71.7%). Table 3 shows the demo-
graphic characteristics, diagnosis at admission, incidence
of associated organ failure, and sources of infection of
patients in the DCCT and non-DCCT groups. Sex distri-
bution, age, APACHE II score, and lactate levels were
very similar in the two groups.
Significant differences between the two groups were
found in diagnosis at admission and source of infection.
In the DCCT group, the percentage of patients with med-
ical diagnoses was higher (79.9% versus 59.6%; P < 0.001)
and the percentage with emergency surgical diagnoses
was lower (15.2% versus 33%; P < 0.001). The most com-
mon source of sepsis was pneumonia in the DCCT group
(59% versus 27.7%; P < 0.001) and abdominal infection in
the non-DCCT group (14.4% versus 33.9%; P < 0.001).
Although the median number of organ failures was the
same in both groups, significant differences were noted
in the organ-failure distribution: respiratory failure was
more common in the DCCT group (74.5% versus 60.1%;
P < 0.001) and renal failure was more common in the
non-DCCT group (68% versus 75.4%; P = 0.007).
In the DCCT group, the most frequently used agents
were b-lactams (n = 320; 82.5%), followed by quinolones
(n = 186; 47.9%), aminoglycosides (n = 158; 40.7%), and
carbapenems (n = 76; 19.6%) (Table 4). These agents were
used in the following combinations: (a) a b-lactam plus an
aminoglycoside or a quinolone or a macrolide (n = 312;
80.4%); the most common combination in this group was
a b-lactam plus a quinolone (n = 163; 52.2%); (b) a carba-
penem plus an aminoglycoside or a quinolone or a macro-
lide (n = 68; 17.5%); the most common combination in
this group was a carbapenem plus an aminoglycoside (n =
46; 67.6%); and (c) a b-lactam plus a carbapenem (n = 8;
2.1%), usually associated with an aminoglycoside (n = 6;
75.0%) (data not shown in table). It is noteworthy that
DCCT consisted only of a b-lactam or carbapenem plus a
macrolide and/or an aminoglycoside and/or a quinolone
in 311 (80%) patients; thus, other antimicrobials (antifun-
gals, anti-gram-positive agents, and so on) were also admi-
nistered in DCCT in only 75 (20%) (data not shown).
Predictors of mortality
In the univariate analysis, factors significantly associated
with mortality were gender, age, APACHE II score, lac-
tate levels, source of infection, and DCCT (Table 5).
Mortality was significantly lower in the DCCT group
(34.0% versus 40%; P = 0.042). In the multivariate analysis
(Table 6), including the variables that were significantly
associated with mortality in the univariate analysis,
higher age (OR, 1.023; 95% CI, 1.014 to 1.032; P < 0.001),
male sex (OR, 1.350; 95% CI, 1.041 to 1.750; P = 0.024),
higher APACHE II score (OR, 1.099; 95% CI, 1.099 to
1.141; P < 0.001), and community-acquired infection
(OR, 1.487; 95% CI, 1.119 to 1.974; P = 0.006) was asso-
ciated with higher mortality, whereas urologic focus of
infection (OR, 0.241; 95% CI, 0.102 to 0.569; P = 0.001)
and DCCT were associated with lower mortality (OR,
0.699; 95% CI, 0.522 to 0.936; P = 0.016).
Table 2 Antibiotic distribution in the entire cohort and in patients with community-acquired and nosocomial sepsis
Antibiotics Global
n = 1,372
Community-acquired
n = 1,022 (74.5%)
Nosocomial
n = 350 (25.5%)
P
b-lactams 902 (65.7%) 708 (69.3%) 194 (55.4%) <0.001
Carbapenems 345 (25.1%) 218 (21.3%) 127 (36.3%) <0.001
Quinolones 282 (20.6%) 241 (23.6%) 41 (11.7%) <0.001
Aminoglycosides 183 (13.3%) 114 (11.2%) 69 (19.7%) <0.001
Macrolides 60 (4.4%) 54 (5.3%) 6 (1.7%) 0.004
Anti-gram-positive 161 (11.7%) 96 (9.4%) 65 (18.6%) <0.001
Antifungals 38 (2.8%) 20 (2.0%) 18 (5.1%) 0.004
Others 151 (11.0%) 111 (10.9%) 40 (11.4%) 0.767
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For the DCCT-combination treatments associated with
reductions in mortality, the results of the analysis,
excluding patients who died within the first 6 hours, were
similar to the results including these patients; hence,
no evidence of immortal bias was found in our results.
Discussion
This secondary analysis of the Edusepsis study reveals inter-
esting data about the patterns of antibiotic prescription
in patients with severe sepsis and septic shock and about
the characteristics of patients receiving combination ther-
apy, including antimicrobials, with different mechanisms of
action (DCCTs) versus those receiving either monotherapy
or any other combinations of antimicrobials (non-DCCTs).
Our study confirms the increased survival in patients admi-
nistered DCCTs (b-lactams plus aminoglycosides, quino-
lones, or macrolides/clindamycin) within the first 6 hours
of severe sepsis presentation. We excluded patients that
Table 3 Comparisons of patients treated with DCCT or non-DCCT
DCCT group
n = 388 (28.3%)
Non-DCCT group
n = 984 (71.7%)
P
General data
Sex (male) 247 (63.7%) 590 (60%) 0.219
Age (years) 60.88 ± 16.79 62.78 ± 15.96 0.057
APACHE II 21.35 ± 7.43 21.47 ± 7.58 0.790
Lactate (mM) 36.37 ± 26.99 35.22 ± 26.93 0.578
Diagnosis on admission
Medical 310 (79.9%) 583 (59.6%) <0.001
Trauma 3 (0.8%) 22 (2.2%) 0.074
Emergency surgery 59 (15.2%) 323 (33%) <0.001
Elective surgery 16 (4.1%) 50 (5.1%) 0.487
Type of infection
Abdominal 56 (14.4%) 334 (33.9%) <0.001
Urologic 44 (11.3%) 138 (14%) 0.216
Meningitis 5 (1.3%) 45 (4.6%) 0.002
Skin and/or soft-tissue 6 (1.5%) 48 (4.9%) 0.003
Catheter 4 (1%) 20 (2%) 0.256
Others 31 (8%) 107 (10.9%) 0.134
More than one focus 13 (3.4%) 19 (1.9%) 0.162
Organ failure
Number of organ failures 2.98 ± 1.26 2.98 ± 1.25 0.955
Hemodynamic 319 (82.2%) 810 (82.3%) 0.999
Respiratory 289 (74.5%) 591 (60.1%) <0.001
Renal 264 (68%) 742 (75.4%) 0.007
Hepatic 61 (15.7%) 177 (18%) 0.343
Hematologic 94 (24.2%) 250 (25.4%) 0.679
Coagulation 131 (33.8%) 371 (37.7%) 0.191
Mortality 132 (34%) 394 (40%) 0.042
Table 4 Antibiotic prescription in patients treated with DCCT or non-DCCT
Antibiotics Non-DCCT group
n = 984 (71.7%)
DCCT group
n = 388 (28.3%)
P
b-Lactams 582 (59.1%) 320 (82.5%) <0.001
Carbapenems 269 (27.3%) 76 (19.6%) 0.003
Quinolones 96 (9.8%) 186 (47.9%) <0.001
Aminoglycosides 25 (2.5%) 158 (40.7%) <0.001
Macrolides 7 (0.7%) 53 (13.7%) <0.001
Anti-gram-positive 120 (12.2%) 41 (10.6%) 0.456
Antifungals 21 (2.1%) 17 (4.4%) 0.028
Others 121 (12.3%) 30 (7.7%) 0.016
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received antimicrobial therapy after 6 hours of severe sepsis
diagnosis from this analysis, because strong evidence indi-
cates that early administration increases survival in patients
with severe sepsis or septic shock [4,5,10].
Appropriate empiric antimicrobial therapy is crucial for
the survival of sepsis patients [4,5]. Formerly, multidrug-
resistant pathogens were found almost exclusively in
nosocomial infections. However, community-acquired
infections are now often caused by antibiotic-resistant
bacteria (for example, extended-spectrum b-lactamase-
producing Enterobacteriaceae, multidrug-resistant Pseu-
domonas aeruginosa, or methicillin-resistant Staphylococ-
cus aureus) [14,15]. This striking change in epidemiology
may explain why the initial therapy frequently includes a
combination of different antimicrobial agents [16].
b-Lactams, including carbapenems, are the most com-
monly used antibiotics in the critical care setting [17].
Likewise, this antibiotic family constitutes the mainstay
of empiric treatment in patients with severe sepsis or
septic shock, whether administered alone or in combina-
tion with other antimicrobials. Carbapenems are more
frequently prescribed in patients with nosocomial sepsis,
although it is worth mentioning that one in five patients
with community-acquired sepsis is treated empirically
with a carbapenem. This may reflect the increase in mul-
tidrug-resistant gram-negative pathogens in the commu-
nity [14]. Carbapenems might have been analyzed in
conjunction with the rest of b-lactams. However, we
decided to analyze them separately from other b-lactams
because of the broader-spectrum, major role in empiric
antibiotic therapy and the widespread use in the ICU.
Quinolones are used mainly in community-acquired
infections and in combination therapy [18]. The extended
use of quinolones in combination therapy in patients
with severe community-acquired pneumonia may explain
the increasing rate of quinolone resistance among noso-
comial gram-negative pathogens [18,19].
Numerous studies have evaluated the likely superiority
of combination therapy in patients with diverse types of
infections. A French multicenter study of critical patients
with acute peritonitis found no difference in the rate of
therapeutic failure or length of antibiotic treatment when
b-lactams were administered alone or in combination
with aminoglycosides, concluding that aminoglycosides
should be added only when an infection by Pseudomonas
spp or Enterococcus spp is suspected [20]. Two rando-
mized clinical trials found no benefits of combination
therapy over monotherapy in patients with ventilator-
Table 5 Univariate analysis of factors associated with in-hospital mortality
Global
n = 1,372
Survivors
n = 846 (61.7%)
Nonsurvivors
n = 526 (38.3%)
P
General data
Sex (male) 837 (61.0%) 489 (57.8%) 348 (66.2%) 0.002
Age (years) 62.2 ± 16.2 59.80 ± 16.81 66.16 ± 14.39 <0.001
APACHE II 21.4 ± 7.5 19.20 ± 6.86 25.09 ± 7.17 <0.001
Lactate (mM) 35.6 ± 26.9 31.09 ± 22.54 43.09 ± 31.69 <0.001
Type of infection
Pneumonia 502 (36.6%) 289 (34.2%) 213 (40.5%)
Abdominal 390 (28.4%) 228 (27%) 162 (30.8%)
Urologic 181 (13.3%) 142 (16.8%) 40 (7.6%)
Meningitis 50 (3.6%) 40 (4.7%) 10 (1.9%) <0.001
Skin and soft-tissue 54 (3.9%) 37 (4.4%) 17 (3.2%)
Catheter 24 (1.7%) 15 (1.8%) 9 (1.7%)
Others 138 (10.1%) 78 (9.2%) 60 (11.4%)
More than one focus 32 (2.3%) 17 (2%) 15 (2.9%)
Community acquired 1,022 (74.5%) 666 (78.7%) 356 (67.7%) <0.001
DCCT 388 (28.3%) 256 (30.3%) 132 (25.1%) 0.042
Table 6 Multivariate analysis of risk factors for mortality
Factors OR CI (95%) P
Age (years) 1.023 (1.014-1.032) <0.001
Sex (male) 1.350 (1.041-1.750) 0.024
APACHE II 1.099 (1.099-1.141) <0.001
Community-acquired 1.487 (1.119-1.974) 0.006
DCCT 0.699 (0.522-0.936) 0.016
Focus of infection
Pneumonia 0.784 (0.358-1.718) 0.543
Abdominal 0.595 (0.269-1.317) 0.200
Urologic 0.241 (0.102-0.569) 0.001
Meningitis 0.357 (0.122-1.046) 0.060
Skin and soft-tissue 0.424 (0.157-1.141) 0.089
Catheter 0.441 (0.135-1.445) 0.177
Others 0.772 (0.330-1.806) 0.551
More than one focus 1
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associated pneumonia [21,22]. Moreover, in one trial,
monotherapy was associated with lower rates of thera-
peutic failure, superinfection, and side effects [22].
Conversely, diverse studies have demonstrated lower
mortality and length of stay in patients with pneumococcal
bacteremia or with community-acquired pneumonia
receiving combination therapy, including a b-lactam plus a
macrolide or a quinolone, than in those receiving mono-
therapy [23-25]. In these studies, the benefits seem to be
restricted to more-severe patients or to those in septic
shock [18,23]. Conversely, a recent retrospective study
concluded that, in bacteremia caused by gram-negative
bacilli, combination therapy with b-lactams and fluoroqui-
nolones was associated with a reduction in 28-day crude
mortality only among less severely ill patients [7].
Two meta-analyses of studies performed in patients with
gram-negative bacteremia or sepsis found no benefit of
combination therapy over monotherapy, except when bac-
teremia was caused by multidrug-resistant bacteria or
Pseudomonas spp [26,27]. Moreover, higher rates of side
effects (mainly nephrotoxicity) were reported in the group
of patients treated with b-lactam antibiotics plus amino-
glycosides. More recently, a meta-analytic/meta-regression
study that included 50 studies found that combination
antibiotic therapy improves survival, particularly in septic
shock patients, but may be harmful to less severely ill
patients [28].
Nevertheless, few data are available about the impact
on the outcome of combination therapy in large cohorts
of patients with severe sepsis or septic shock. A recent
propensity-matched analysis concluded that, in patients
with septic shock, the use of combination therapy with
two or more antibiotics of different mechanistic classes
was associated with lower 28-day mortality, shorter ICU
stay, and lower in-hospital mortality [10].
Our results confirm that combination therapy, including
two or more antimicrobials with different mechanisms of
action (b-lactams in combination with aminoglycosides,
fluoroquinolones, or macrolides/clindamycin), adminis-
tered within the first 6 hours of sepsis presentation is an
independent protective factor against in-hospital mortality.
Interestingly, severity of illness measured by APACHE II
score, basal lactate levels, and the presence of hemody-
namic failure did not differ between patients receiving
DCCTs and those receiving non-DCCTs.
The choice of empiric antimicrobial therapy is based on
the clinical presentation of the infection, the characteristics
of the patient, the local ecology, and previous antibiotic
exposure. Reducing the antibiotic pressure and side effects
are the main reasons for choosing monotherapy. Conver-
sely, the main reason for prescribing combination therapy
for critically ill sepsis patient is to broaden the antimicro-
bial spectrum in an attempt to ensure the coverage of all
likely pathogens. Our results permit us to speculate that
the synergistic mechanisms of different antimicrobial com-
binations, or the immunomodulatory effects described with
macrolides and quinolones, may be of clinical transcen-
dence in patients with severe sepsis or septic shock [29-31].
Our study has several limitations. First, a major limita-
tion in our study is the lack of microbiology data due to
the initial study design. Accordingly, no data are available
on antibiotic susceptibility, appropriateness of antimicro-
bial therapy, or the presence of bacteremia. Appropriate
antimicrobial therapy based on culture results was an
important determinant of survival in a large cohort of
patients with severe sepsis [32].
Second, because of the absence of microbiology data,
we cannot explore whether the positive impact on mor-
tality observed with DCCTs is related to a synergistic
effect of two mechanistically distinct antibiotics or a
broader range of coverage with two or more agents.
Third, we did not evaluate source control and other
important measures included in the Surviving Sepsis
Campaign care bundles.
Fourth, this is a secondary analysis of an observational
study. Nevertheless, properly designed observational stu-
dies with the appropriate analytic approach can provide
valuable information on treatment effectiveness [4].
However, our study has also important strengths. We
prospectively enrolled a large cohort of ICU patients with
severe sepsis and septic shock in a short time and moni-
tored them until death or hospital discharge, resulting in
a homogeneous database with high quality-control mea-
sures that assure data validity [4]. Finally, our conclusions
are strengthened by absence of immortal bias.
Conclusions
b-Lactams, including carbapenems, are the mainstay of
empiric therapy in patients with severe sepsis and septic
shock. Carbapenems are more frequently prescribed in
patients with nosocomial sepsis, although up to one in
five patients with community-acquired sepsis is treated
empirically with a carbapenem. Our study supports the
hypothesis that early administration of antimicrobials
with different mechanistic targets is associated with
decreased in-hospital mortality. Our findings extend
those of the propensity-matched analysis in patients with
septic shock published by Kumar et al. [10] because we
also included patients with severe sepsis, underlining the
urgent need for well-designed randomized controlled
trials to evaluate the clinical benefit of DCCTs in criti-
cally ill sepsis patients.
Key messages
• b-Lactams, including carbapenems, are the antibio-
tics most usually used in the critical care setting.
• Although carbapenems are more frequently pre-
scribed in patients with nosocomial sepsis, one in five
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patients with community-acquired sepsis is treated
empirically with a carbapenem.
• Urologic focus of infection is associated with the
lowest mortality rate in patients with severe sepsis or
septic shock.
• In our series, the mortality rate was significantly
lower in patients receiving DCCTs than in those
receiving non-DCCTs.
• A DCCT in empiric therapy is a protective factor for
mortality in patients with severe sepsis or septic shock.
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